[HTML][HTML] Subcutaneous REGEN-COV antibody combination to prevent Covid-19
MP O'Brien, E Forleo-Neto, BJ Musser… - … England Journal of …, 2021 - Mass Medical Soc
Background REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal
antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of …
antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of …
Plasmacytoid dendritic cells in HIV infection
M O'Brien, O Manches, N Bhardwaj - HIV Interactions with Dendritic Cells …, 2012 - Springer
Plasmacytoid dendritic cells (pDCs) are innate immune cells that are specialized to produce
interferon-alpha (IFNα) and participate in activating adaptive immune responses. Although …
interferon-alpha (IFNα) and participate in activating adaptive immune responses. Although …
Phenotypic properties of transmitted founder HIV-1
Defining the virus–host interactions responsible for HIV-1 transmission, including the phenotypic
requirements of viruses capable of establishing de novo infections, could be important …
requirements of viruses capable of establishing de novo infections, could be important …
Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy
Background . Cryptococcal meningitis (CM) is the proximate cause of death in 20%–30% of
persons with acquired immunodeficiency syndrome in Africa. Methods . Two prospective, …
persons with acquired immunodeficiency syndrome in Africa. Methods . Two prospective, …
Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 …
MP O'Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou… - Jama, 2022 - jamanetwork.com
Importance Easy-to-administer anti–SARS-CoV-2 treatments may be used to prevent
progression from asymptomatic infection to symptomatic disease and to reduce viral carriage. …
progression from asymptomatic infection to symptomatic disease and to reduce viral carriage. …
Evidence of dysregulation of dendritic cells in primary HIV infection
RL Sabado, M O'Brien, A Subedi, L Qin… - Blood, The Journal …, 2010 - ashpublications.org
Myeloid and plasmacytoid dendritic cells (DCs) are important mediators of both innate and
adaptive immunity against pathogens such as HIV. During the course of HIV infection, blood …
adaptive immunity against pathogens such as HIV. During the course of HIV infection, blood …
Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study
M O'Brien, E Montenont, L Hu, MA Nardi… - JAIDS Journal of …, 2013 - journals.lww.com
Background: Mechanisms for increased cardiovascular risk in HIV-1-infected adults are
incompletely understood, but platelet activation and immune activation leading to a …
incompletely understood, but platelet activation and immune activation leading to a …
Should we treat acute HIV infection?
M O'Brien, M Markowitz - Current HIV/AIDS Reports, 2012 - Springer
Critical advances in the early diagnosis of HIV now allow for treatment opportunities during
acute infection. It remains unclear whether treatment of acute HIV infection with antiretroviral …
acute infection. It remains unclear whether treatment of acute HIV infection with antiretroviral …
Human immunodeficiency virus type 1 modified to package Simian immunodeficiency virus Vpx efficiently infects macrophages and dendritic cells
N Sunseri, M O'Brien, N Bhardwaj… - Journal of virology, 2011 - Am Soc Microbiol
The lentiviral accessory protein Vpx is thought to facilitate the infection of macrophages and
dendritic cells by counteracting an unidentified host restriction factor. Although human …
dendritic cells by counteracting an unidentified host restriction factor. Although human …
[HTML][HTML] Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
While new vaccines for SARS-CoV-2 are authorized based on neutralizing antibody (nAb)
titer against emerging variants of concern, an analogous pathway does not exist for …
titer against emerging variants of concern, an analogous pathway does not exist for …